Midsize and startup drug developers in the Philadelphia region saw their market capitalization drop by nearly $3.7 billion during the first half of 2022.
Midsize and startup drug developers in the Philadelphia region saw their market capitalization drop by nearly $3.7 billion during the first half of 2022.
